Biosimilars are a
prescription for
better health.

In the U.S., Biosimilars could lead to over $130 billion is savings by 2025, and have been used in over 364 million days of patient therapy.

GrxBiosims

Register Now! GRx+Biosims 2023

GRx+Biosims™ 2023, the premier regulatory science and policy event for the U.S. generics and biosimilars industry, will be held on October 2-4 in North Bethesda, Maryland! Get the latest information directly from Food and Drug Administration experts, understand the latest policy that impacts the industry and gain valuable insights to advance your professional development.  Register now!

Biosimilars in the US

IQVIA Report: Biosimilars in the United States 2023-2027

This in-depth report from IQVIA lays out key forecasts, trends and expectations biosimilar industry. Among the report’s findings, IQVIA found that savings generated from biosimilar medicines could exceed $180 billion in 2027 if we continue expanding patient access to these treatments. Download the report.

Advocacy

The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.

Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market

41

Biosimilars approved in the U.S.

$180

Billion in potential savings for patients and payers

364

Million days of patient therapy where biosimilars were used

150

Million additional days of patient therapy

The Benefits of Biosimilars

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.

This increases access to needed medications for patients, strengthens our economy and benefits our society.

View resources for:

Recent Blogs & Resources

What Patients Are Saying

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
Helen, 41, Winter Springs, Florida treated her non-Hodgkin lymphoma with a biosimilar

“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”

Helen, 41, Florida

Listen to their stories.

You Can Make A Difference

As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.